As PTSD treatment remains a critical unmet need there is heightened public and private interest in identifying new and safe treatments for this devastating disease. This sentiment has been clearly verbalized during the meeting in Washington.

“We appreciate the opportunity to present our approach to PTSD treatment to the House of Representatives Committee on Veteran’s Affairs and look forward to the launch of Phase IIb/III trial with the support and encouragement from the US Congress and relevant government stakeholders within Veteran’s Administration and the DoD,” said Dr. Bogin, Nobilis Therapeutics’ CEO.

Nobilis Therapeutics recently held a pre-IND meeting with the FDA and received a very positive feedback on the proposal to run a late stage clinical trial with its Xenon-based therapeutic candidate. The company plans to submit an IND in the coming weeks.

“This was an incredible opportunity to interface with VA representatives and make them aware of our cutting-edge preclinical work to understand the neurobiology underlying maladaptive emotional memories, and test innovative treatments that can be rapidly translated to humans with PTSD. Given the paucity of effective pharmacotherapies for treating PTSD, I believe that advancing collaborations between government, industry and academia will foster the much-needed breakthroughs in the treatment of this debilitating disorder,” said Dr. Edward Meloni, Assistant Professor of Psychiatry at Harvard-affiliated McLean Hospital.

The company is very encouraged by a recent position statement from the PTSD psychopharmacology working group that identified NMDA receptor blockade as the most promising target in the treatment of PTSD. Given that Xenon is an NMDA receptor antagonist with an exceptional safety profile and strong preclinical and clinical signals of efficacy, if it shows positive results in the upcoming clinical trial, it could become a game changer not only in the treatment of PTSD but in many other psychiatric indications.

About the company

Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using portable device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.